Company overview
Dovendi specializes in the aftermarket domain name industry, acting as a knowledge and sales broker that connects buyers and sellers of previously registered domains. They manage portfolios for partners, facilitate sales transactions, and provide market insights, handling over 250,000 international domains. No offerings specific to life sciences or pharmaceutical procurement, R&D, or vendor services are indicated; the original URL resolves to a domain for sale.
Innosign Nl is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include domain broker, aftermarket domains, domain portfolio management, domain sales, international domains.
Structured facts
- Website
- https://www.innosign.nl/
- Markets served
- United States & Americas
- Keywords
- domain broker, aftermarket domains, domain portfolio management, domain sales, international domains
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What services does Dovendi provide for domain management?
- Dovendi manages domain portfolios for partners, follows up on inquiries, provides sales advice, attaches response forms to domains, and handles the full process from quotes to transfers.
- Does Dovendi operate in pharmaceutical or life sciences sectors?
- No evidence indicates Dovendi offers services tailored to pharma, life sciences, or vendor evaluation; they focus exclusively on aftermarket domain names.
- What are Dovendi's geographical capabilities?
- Dovendi is internationally oriented, managing over 250,000 international domains with contact based in the Netherlands (+31 area code).
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
